The classic psychedelics, psilocybin, LSD, and the brew known as ayahuasca among others, share enough mechanism that people sometimes talk about them as one category. They also differ from each other in ways that matter a great deal, for the experience, the duration, the safety profile, and the contexts where each tends to be used. Treating them as interchangeable is a common mistake, and an avoidable one.
This article compares the three most-discussed members of the family, focusing on what sets them apart rather than what they share. It is an explainer, not a recommendation, and it does not tell anyone how to use anything. The goal is simply to understand why these three substances, often lumped together, are not the same thing.
What they have in common
All three act primarily through agonism at the 5-HT2A serotonin receptor. The acute effects each produces, the perceptual changes, the altered cognition, the emotional intensity, the experiences people describe as mystical or self-transcendent, emerge from broadly similar action on similar receptor systems. The clinical research on all three has pointed toward similar potential applications, including depression, anxiety, end-of-life distress, and addiction. And the mechanism by which they seem to produce therapeutic change, opening a window of cognitive flexibility in which long-held patterns of thought can be revised, appears to be common across the class.
This shared mechanism is also why all three produce cross-tolerance with one another. A person who has recently taken one will find the others weaker than usual for a while, because the receptor system they all lean on needs time to reset. So the family resemblance is real. It is the differences, though, that make the comparison worth doing.
Psilocybin, the most-studied
Psilocybin is the most extensively researched of the three in modern clinical trials. The Hopkins, NYU, Compass Pathways, and other major efforts have used psilocybin specifically, which means its evidence base is the deepest. Its pharmacology is reasonably well characterized too. It is orally active, with onset within an hour, a peak around 90 minutes, and a total duration of roughly four to six hours.
The experience that participants typically report involves intense visual phenomena, often described as organic or earth-toned, strong emotional content, and a high probability of mystical-type experiences at sufficient doses. The cognitive changes tend to feel relatively grounded. Many people report that they keep a sense of meaning and continuity with their ordinary self even at the peak, rather than feeling entirely swept away.
The duration is convenient for clinical settings, since a session can comfortably fit inside a single workday. The afterglow that follows is typically less intense than with longer-acting substances. Between the research base and the manageable timeline, psilocybin has become the default subject of serious study, which is part of why it dominates the conversation.
LSD, the long wave
LSD differs from psilocybin in several ways with real practical weight, and the most obvious is duration. A typical LSD experience lasts eight to twelve hours, and significant effects can run longer. That makes it substantially more demanding logistically. Clinical sessions are hard to fit into a single day, and a full experience effectively occupies a 24-hour period once you account for preparation, the experience itself, and the come-down. Time is the first thing that separates it from the mushroom.
The pharmacology differs in subtler ways too. LSD has affinity for a broader range of receptors than psilocybin, including dopamine and adrenergic receptors, which contributes to a somewhat different subjective profile. The experience is often reported as more energetic or buzzy, with stronger physical activation. Visual phenomena under LSD are frequently described as more geometric and synthetic, in contrast with psilocybin's more organic visuals.
LSD is also far more potent by weight, which is why its doses are measured in micrograms rather than milligrams. That potency is a pharmacological fact about the molecule rather than a how-to, and the practical takeaway for a general reader is simply that the two substances operate on completely different scales. The clinical research base on LSD is smaller than psilocybin's, partly for historical reasons, since the political backlash against LSD in the 1960s effectively halted research for decades. Recent trials have begun rebuilding that evidence base, with promising findings in areas similar to psilocybin's clinical applications.
Ayahuasca, the plant brew
Ayahuasca differs from both psilocybin and LSD in ways that reach past pharmacology into cultural and ceremonial context. It is, to start with, not a single compound but a combination of two plants. One, a vine, contains beta-carboline compounds that act as monoamine oxidase inhibitors. The other, a shrub, contains DMT, a powerful psychedelic that is normally inactive when swallowed. The combination is the whole trick. The MAO inhibitors prevent the DMT from being broken down in the gut, allowing it to be absorbed and reach the brain. Neither plant alone would do much by mouth. Together they make the brew work.
The experience profile is distinct. Onset begins within 30 to 60 minutes of drinking, the peak typically lasts two to three hours, and the total experience runs about four to six hours. That is comparable to psilocybin in overall length, but with a sharper peak. The qualitative character is often described as substantially different from either psilocybin or LSD. Visual content tends to be more vivid and structured, with people frequently reporting elaborate visions that feel narrative or instructive rather than abstract. The emotional content is frequently intense and challenging, and ayahuasca has a reputation for difficult experiences in a way that the other two usually do not.
The physical effects are more pronounced as well. Vomiting, often called the purge, is common and is treated as a meaningful part of the experience in traditional contexts. Diarrhea is also common. The bodily demands of an ayahuasca session are considerable in a way that psilocybin and LSD sessions typically are not, which is one more reason it is not a casual undertaking.
The cultural context is its own dimension. The brew is rooted in indigenous traditions of the Amazon basin, particularly among the Shipibo and several other peoples, where its use happens in ceremonial settings led by experienced ayahuasqueros. The movement of these practices into Western contexts, through retreats and through the syncretic religious traditions of Santo Daime and União do Vegetal, has been a substantial cultural development over the past several decades, and not an uncomplicated one. Unlike the other two, ayahuasca arrives already wrapped in a living tradition that shapes how it is understood and used.
Practical differences
The practical gaps between the three are wide enough to explain why one might be preferred over another in different settings.
For clinical research and therapy, psilocybin's shorter duration, well-characterized pharmacology, and deeper evidence base have made it the leading candidate. LSD trials are growing but lag behind. Ayahuasca research is more limited, partly for regulatory reasons and partly because its cultural context is genuinely hard to fit into standard clinical trial designs.
For the way each tends to be used outside the clinic, the same factors push in different directions. Psilocybin's shorter duration and grounded profile, along with its increasing tolerance in some jurisdictions, have made it the most commonly chosen. People who want a longer or more energetic experience tend toward LSD. Ayahuasca's physical demands and ceremonial framing make it less of a casual choice and more of a deliberate, often guided, undertaking.
For ceremonial or spiritual use, ayahuasca's rooted tradition, its established ceremonial structures, and the tendency of the experience toward content that feels meaningful in religious terms have made it central to several religious practices. Psilocybin's connection to Mazatec ceremonial use carries similar significance. LSD, by contrast, lacks an established traditional ceremonial framework, which is part of why it sits more in the recreational and research worlds than the religious one.
Safety considerations differ
The safety profiles overlap but are not identical, and the differences are worth stating plainly. Psilocybin and LSD both have low physiological toxicity. Lethal doses through pharmacological action alone are extremely high, well above anything used in research or recreationally. The main acute safety concerns are modest cardiovascular effects, accidents during the experience, and the psychological difficulty of a hard experience.
Ayahuasca carries an additional and serious consideration that the other two do not. The MAO inhibitors in the brew interact dangerously with several common medications, including SSRIs and certain other antidepressants, some over-the-counter cold medicines, and certain foods. These interactions can be life-threatening, not merely unpleasant. This is a warning rather than a guide. Anyone on any medication who is even considering ayahuasca needs a qualified medical professional to assess the combination first, and should never assume it is safe. The danger here is real and has caused serious harm.
Across all three, the psychological risks include the possibility of a difficult experience and, rarely, the possibility of triggering or unmasking a psychotic episode in vulnerable individuals. The standard exclusion criteria used in clinical trials, including a personal or family history of psychotic disorders and certain other psychiatric conditions, apply broadly across the whole class. None of these substances is appropriate for everyone, and the screening exists for good reasons.
What these comparisons suggest
The classic psychedelics are not interchangeable. They share enough mechanism to belong to the same category and to be discussed together in many contexts. They also differ enough that the choice of which to use, or which to study, has substantial practical consequences.
For most people new to the topic, psilocybin is the most useful starting point for understanding, because it has the most robust research base and the shortest duration. LSD is useful as a comparison case for grasping what varies across the class. And ayahuasca is important to understand for its cultural and historical context, even for people who would never consider using it. The honest description of the field is that these differences are only starting to be properly characterized, and the comparative research is still developing. Where one substance has been studied thoroughly and another has not, the comparisons are necessarily uneven. The next decade of research should sharpen these distinctions considerably.